1. Home
  2. BGM

as 06-20-2025 2:31pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

NYSE

BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.

Founded: 2019 Country:
China
China
Employees: 323 City: N/A
Market Cap: 2.5B IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 78.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.20 EPS Growth: N/A
52 Week Low/High: $5.25 - $17.17 Next Earning Date: 08-13-2025
Revenue: $25,097,951 Revenue Growth: -45.99%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

BGM Daily Stock ML Predictions

Share on Social Networks: